06:48:03 Europe / Stockholm

Share price & Turnover

Share price change and turnover during the day of this press release

Calendar

2025-06-25 Annual General meeting
2025-03-05 Year-end Report 2024
2024-11-27 Quarterly Report 2024-Q3
2024-09-12 Quarterly Report 2024-Q2
2024-09-12 Extra General Meeting 2024
2024-06-28 Quarterly Report 2024-Q1
2024-06-27 Ex-date Ordinary Dividend SOFTX 0.00 NOK
2024-06-26 Annual General meeting
2024-03-20 Year-end Report 2023
2023-10-26 Quarterly Report 2023-Q3
2023-09-26 Quarterly Report 2023-Q2
2023-06-21 Annual General meeting
2023-06-21 Quarterly Report 2023-Q1
2023-03-30 Ex-date Ordinary Dividend SOFTX 0.00 NOK
2023-02-17 Year-end Report 2022
2022-12-09 Extra General Meeting 2022
2022-10-26 Quarterly Report 2022-Q3
2022-08-15 Quarterly Report 2022-Q2
2022-04-28 Quarterly Report 2022-Q1
2022-04-19 Ex-date Ordinary Dividend SOFTX 0.00 NOK
2022-04-17 Annual General meeting
2022-02-16 Year-end Report 2021
2021-12-29 Extra General Meeting 2021
2021-11-17 Quarterly Report 2021-Q3
2021-09-08 Quarterly Report 2021-Q2
2021-04-29 Quarterly Report 2021-Q1
2021-04-14 Ex-date Ordinary Dividend SOFTX 0.00 NOK
2021-04-13 Annual General meeting
2021-02-09 Year-end Report 2020
2020-12-14 Quarterly Report 2020-Q3
2020-09-30 Quarterly Report 2020-Q2
2020-07-01 Ex-date Ordinary Dividend SOFTX 0.00 NOK
2020-06-30 Quarterly Report 2020-Q1
2020-06-30 Annual General meeting
2019-12-20 Extra General Meeting 2019
2019-06-27 Annual General meeting
2019-06-03 Ex-date Ordinary Dividend SOFTX 0.00 NOK
2018-07-02 Split SOFTX 1:50

Description

CountryNorway
ListEuronext Growth Oslo
SectorHealth care
IndustryMedical technology
SoftOx Solutions är ett norskt medicintekniskt bolag. Bolaget har utvecklat en egenpatenterad lösning baserad på ättiksyra för behandling av kroniska sår hos patienter. Lösningen används för att eliminera infektioner i samband med biofilmer, vilket består av olika kluster av bakterier. En del av läkemedelsutvecklingen sker i samarbete med övriga forskningsinstitut. SoftOx Solutions etablerades under 2012 och har sitt huvudkontor i Oslo, Norge.
2023-03-14 14:20:25
The Norwegian Environment Agency has today approved SoftOx's biocidal product
family for hand and surface disinfection for use in the Norwegian market. The
approval is a mutual recognition in sequence based on the approval by the
Swedish Chemicals Agency (KemI) on 19 October 2022. With this approval, the
company is now approved for up to 10 years in line with Biocidal Products
Regulation.

Decision
"The Norwegian Environment Agency grants SoftOx Solutions AS an authorisation
for the biocidal product family SoftOx Disinfectants on the Norwegian market.
The authorisation is granted from 9 March 2023 to 17 October 2032 with the
authorisation number NO-2023-0240."

For further information, please contact:
Geir Almås, Executive Chairman of SoftOx Solutions AS
Christian Harstad, Interim CEO of SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a medtech and
clinical-stage pharmaceutical company based in Oslo, Norway, with the goal of
reducing the spread of infection and emergence of antimicrobial resistance. For
more information on SoftOx, visit www.soft-ox.com